The Competition Commission of India (CCI) has approved the acquisition involving Micro Life Sciences, paving the way for further consolidation in the pharmaceutical and medical devices space. The regulator’s nod signifies that the transaction is unlikely to harm competition within the domestic market, reflecting its alignment with industry growth and compliance standards. This clearance comes at a time when India’s healthcare sector is experiencing heightened investment activity, particularly in life sciences, diagnostics, and medical technology.